Shan‐Liang Sun

728 citations
37 papers · 465 indexed · h-index 13
Topics
Protein Degradation and Inhibitors (5 papers)Ubiquitin and proteasome pathways (4 papers)Computational Drug Discovery Methods (4 papers)

In The Last Decade

Shan‐Liang Sun

34 papers receiving 460 citations

Peers

Shan‐Liang Sun
Comparison fields: 5 of 74
  • Molecular Biology 311
  • Oncology 117
  • Cancer Research 69
  • Immunology 67
  • Hematology 52
Replace Sachiko Sakakibara with:
Sachiko Sakakibara Japan
Olaf Witt Germany
Sharon Benzeno United States
Malia B. Potts United States
Sarah Mackenzie United States
Tolou Shadbahr Finland
Felix Kartnig Austria
Nuria Ajenjo Spain
Yuki Ishii Japan
Mingsong Shi China
Shan‐Liang Sun relative to Sachiko Sakakibara Japan Sachiko Sakakibara's profile →
Citations per field
00.5×10×15×19.4×
Sachiko Sakakibara · 1×
Citations per year

Countries citing papers authored by Shan‐Liang Sun

Since Specialization
Citations

This map shows the geographic impact of Shan‐Liang Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shan‐Liang Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shan‐Liang Sun more than expected).

Fields of papers citing papers by Shan‐Liang Sun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shan‐Liang Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shan‐Liang Sun. The network helps show where Shan‐Liang Sun may publish in the future.

Co-authorship network of co-authors of Shan‐Liang Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Shan‐Liang Sun. A scholar is included among the top collaborators of Shan‐Liang Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shan‐Liang Sun. Shan‐Liang Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 5
2 1
3 9
4 0
5 8
6 16
7 0
8 17
9 3
10 2
11 3
12 2
13 22
14 9
15 18
16 4
17 3
18 24
19 14
20 11

About Shan‐Liang Sun

Shan‐Liang Sun is a scholar working on Genetics, Hematology and Oncology, having authored 37 papers that have together received 465 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (5 papers), Ubiquitin and proteasome pathways (4 papers) and Computational Drug Discovery Methods (4 papers). The work is most often cited by research in Hematology (52 citations), Cancer Research (69 citations) and Molecular Biology (311 citations). Shan‐Liang Sun has collaborated with scholars based in China, Netherlands and United States. Frequent co-authors include Nian‐Guang Li, Rob Leurs, Iwan J. P. de Esch, Chris de Graaf, Martine J. Smit, Marta Arimont, Zhi‐Hao Shi, Tian‐Yuan Fan, Yue Zhong and Min Chen. Their work appears in journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026